| abstract |
Formula (I): [Where: R 2 has the formula-(Ar 1 ) m- (Alk 1 ) p- (Z) r- (Alk 2 ) s -Q, where Ar 1 is an optionally substituted aryl or heteroaryl group And Alk 1 and Alk 2 are optionally substituted divalent C 1 -C 3 alkylene or C 2 -C 3 alkenylene groups, and m, p, r and s are independently 0 or 1 and Z is -O-, -S-,-(C = O)-,-(C = S)-, -SO 2- , -C (= O) O-, -C (= O) NR A- , -C (= S) NR A- , -SO 2 NR A- , -NR A C (= O)-, -NR A SO 2 -or -NR A- (where R A is hydrogen Or is a C 1 -C 6 alkyl), and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic group); R 3 is hydrogen, an optional substituent, or an optionally substituted (C 1 -C 6 ) alkyl, aryl or heteroaryl group; and R 4 is a carboxyester, carboxyamide or sulfonamido group] These compounds are inhibitors of HSP90 in vitro or in vivo and are particularly useful for the treatment of cancer. |